Incyte Corp (INCY, $62.58) Faces Downtrend: Analyzing Shareholder Returns and Economic Performance
Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.
Incyte Corp (INCY, $62.58) finds itself in the midst of a bearish trend, as indicated by A.I.dvisor's prediction of a potential Downtrend continuation. Shareholders have endured a challenging period, with a notable 38% decline in share price over the past three years and an additional 19% drop in the last quarter. To gain a comprehensive understanding of the company's current situation, it is essential to examine the correlation between shareholder returns and Incyte's underlying economics.
Over the past three years, while the broader market has returned approximately 40%, shareholders of Incyte have faced a contrasting experience with a significant decline of 38%. This divergence raises questions about the company's economic performance and its ability to generate returns for its shareholders.
Delving deeper into Incyte's economic performance, it becomes crucial to analyze whether the company's financials align with the disappointing shareholder returns. By scrutinizing key indicators, such as revenue growth, profitability, and efficiency, we can shed light on the underlying factors contributing to the company's stock performance.
Incyte Corp's economic performance has a critical role to play in determining its future prospects. By assessing the correlation between shareholder returns and the company's financial metrics, we can better understand whether there are any disparities or potential catalysts that may drive a turnaround. This analysis provides valuable insights for investors seeking to navigate the evolving landscape of Incyte Corp and make informed decisions regarding their investment strategy.
It is essential to approach Incyte Corp's current bearish trend with a comprehensive understanding of its underlying economics and the factors influencing its share price. By staying informed and aware of the correlation between shareholder returns and the company's financial performance, investors can make more informed decisions about their investment in Incyte and evaluate its future potential.
INCY sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for INCY moved below the 200-day moving average on April 09, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where INCY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on May 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INCY broke above its upper Bollinger Band on April 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INCY entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on April 15, 2025. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.147) is normal, around the industry mean (14.691). P/E Ratio (298.050) is within average values for comparable stocks, (62.716). Projected Growth (PEG Ratio) (0.107) is also within normal values, averaging (1.861). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.746) is also within normal values, averaging (253.146).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of drugs
Industry Biotechnology